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Abstract
Themain objectives of this study were to describe the characteristics of children with inﬂuenza infection during the postpandemic outbreak, and
to compare sociodemographic and clinical data between patients who required hospitalization and those managed on an outpatient basis with a
matched case–control study design. This is a multicentre paediatric study in Spain that included patients aged 6 month to 18 years in whom
inﬂuenza infection was conﬁrmed by real-time reverse transcription–polymerase chain reaction between December 2010 and March 2011.
Among the 143 admitted patients, the main reason for admission was respiratory failure (123/143). In 55 there was some previously known
disease. The median age was lower in patients without comorbidity (1.8 years: interquartile range 1.0–3.0 versus 5.3 years: interquartile range
1.3–10.7); p <0.01). The lag time from onset of symptoms to starting antiviral treatment was correlated with the length of hospital stay (Rho
Spearman = + 0.32; p 0.01). Twenty patients required admission to the paediatric intensive care units, all due to respiratory failure. Children
with chest X-ray opacities in more than one quadrant more frequently required admission to intensive care. Having a neurological disease
conferred the highest risk of requiring hospitalization (OR 17.18) in a multivariate analysis. This study concludes that inﬂuenza in the paediatric
population requiring hospitalization during the postpandemic season affectedmainly children with neurological or pulmonary comorbidities and
children of parents with a lower educational level. Most of the inﬂuenza infections caused respiratory symptoms, although neurological
manifestations were also observed. Early initiation of oseltamivir was associated with a shorter length of hospital stay.
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Introduction
During 2009 and 2010 the new inﬂuenza virus, A(H1N1)
pdm09, spread worldwide. Most of the inﬂuenza infections
during the pandemic season were caused by this novel virus
and, typically, the infection caused a mild respiratory disease in
children, but severe manifestations and mortality also
occurred [1,2]. Although the most common clinical manifes-
tations were similar to those caused by previous circulating
inﬂuenza viruses [3], severe manifestations were slightly more
frequent with the inﬂuenza A(H1N1)pdm09 virus [4,5],
especially in children with respiratory or neurological comor-
bidities [2,6].
It is well-known that novel inﬂuenza viruses caused
morbidity and mortality during previous postpandemic out-
breaks [7]. Inﬂuenza caused by the novel virus was expected to
occur again during the ﬁrst postpandemic season and to
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co-circulate with previous inﬂuenza viruses. In autumn 2010,
the World Health Organization gave advice on maintaining
awareness of changes in the epidemiology and clinical expres-
sion of the disease [8].
Recently, Rahamat-Langendoen et al. [4] published a study
comparing prepandemic, pandemic and postpandemic inﬂuenza
cases in a single institution including patients of all ages.
Poulakou et al. [9] have also described the disease in adults and
children who required intensive care unit admission during the
postpandemic period. As far as we know, there is still not a
speciﬁc paediatric report that assesses the clinical and
epidemiological characteristics of patients with inﬂuenza
infection after the 2009 pandemics. The main objectives of
this study are to describe the epidemiology and clinical
characteristics of those patients with inﬂuenza infections
during the 2010–2011 inﬂuenza outbreak, and to compare
sociodemographic and clinical data between patients who
required hospitalization and those managed on an outpatient
basis.
Patients and Methods
This is a multicentre paediatric study in Spain. Hospitalized
patients and outpatients were recruited in public Spanish
National Health Service centres. We carried out a multicentre
study in 17 hospitals from seven Spanish regions (Andalusia,
the Basque Country, Castile and Leon, Catalonia, Madrid,
Navarre and Valencia Community). Two of these hospitals
(Hospital Sant Joan de Deu and Hospital Vall d’Hebron, both of
the province of Barcelona) were paediatric hospitals and the
others were general hospitals with paediatric departments.
We included patients aged 6 month to 18 years with inﬂuenza
syndrome in whom inﬂuenza infection was conﬁrmed by real-
time RT-PCR between December 2010 and March 2011. A
prospective matched case–control design was used to com-
pare epidemiological and clinical characteristics between
children who required hospital admission (cases) and children
who were treated on an outpatient basis (controls). Controls
were matched with each case according to age (3 years),
date of hospitalization (10 days) and province of residence.
Patients who could not be matched according to date of
hospitalization and province of residence were excluded from
the case–control analysis. Sociodemographic and clinical data
were gathered using a standard form that was completed by a
trained medical interviewer during the hospitalization or at the
outpatient clinics. Seasonal and pandemic inﬂuenza vaccination
and pneumococcal conjugate vaccination status for any of the
commercialized vaccines were also recorded. Information on
the vaccination status was obtained from hospital medical
records or vaccination card; if neither was available, primary
healthcare centre registers were consulted. Patients were
considered correctly vaccinated if they had received at least
two doses of inﬂuenza vaccine (including the 2010–2011
inﬂuenza virus vaccine strains), the last one >14 days before
the onset of inﬂuenza symptoms, or only one dose if they were
older than 9 years old, according to the recommendations of
the American Academy of Pediatrics and the American
Advisory Committee on Immunization Practices. Patients
were considered correctly vaccinated for pneumococcal
conjugated vaccine if they had received the last dose of
vaccine at least 14 days before the onset of symptoms and if
the number of doses for age was in agreement with the
vaccines’ factsheets. Parental sociodemographic and health
data were also collected.
Descriptive statistics for non-continuous variables are
described using absolute frequencies and rates, and data
comparisons between cases and controls were performed
using McNemar test. Continuous non-normally distributed
variables are described as medians and interquartile ranges
(IQR, 25–75%) and compared using the paired t-test. A
multivariate analysis was performed to estimate the adjusted
odds ratio of several variables as potential risk factors for
hospitalization. The multivariate analysis used a conditional
logistic regression model with backward selection of variables
with a cut-off point of p <0.1 and ‘hospital admission’ as the
output variable. As a measure of goodness of ﬁt we calculated
the Hosmer–Lemeshow test and the predictive accuracy of the
model was determined by calculating the area under the curve.
For statistical analysis of the admitted patients, data
comparisons were performed using Pearson’s chi-square test
or Fisher’s exact test when the expected count in any category
was <5. Continuous non-normally distributed variables were
compared using the Mann–Whitney U test.
Values of p <0.05 were considered statistically signiﬁcant.
The statistical analysis was made using the SPSS® V19 FOR
WINDOWS® package (SPSS Inc., Chicago, IL, USA).
The study was approved by each participating hospital’s
institutional ethics committee and written informed consent
was waived.
Results
During the study, 323 children were recruited (143 hospital-
ized and 180 outpatients). Of the 143 hospitalized children, 43
(30%) were in paediatric hospitals and the others (100; 70%)
were in paediatric departments of general hospitals. Overall,
the median age was 2.9 years (IQR: 1.2–6.7). Of the 323
children, 163 (50%) were male and 247 (76%) had no
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pre-existing condition. The main previously known comorbid-
ities were pulmonary diseases (mainly asthma) in 41 (13%)
patients, neurological and neuromuscular diseases in 27 (8%),
and primary or secondary immunodeﬁciencies in eight (2%).
Eleven (3%) patients had two or more pre-existing conditions.
A total of 266 (82%) patients were Caucasian.
Only eight (2%) of the 323 patients were correctly immu-
nized with seasonal and pandemic inﬂuenza vaccines. Of those,
six had some comorbidity. Only one of the 126 (<1%) children
who were <2 years old was correctly vaccinated.
On the other hand, 102 (32%) of the 323 patients were fully
immunized with some of the commercialized conjugated
pneumococcal vaccines (PCV7, PCV10 or PCV13). Most of
them (80 of the 102; 78%) were previously healthy children.
Hospitalized patients
The main clinical and epidemiological variables of the 143
admitted patients are shown in Table 1. Antiviral treatment
was given to 69 of 111 (48%). In 32 patients data on antiviral
treatment were not recorded. Median time to initiation of
antiviral treatment after onset of clinical symptoms was 4 days
(IQR: 2–7). Length of hospital stay was higher in patients that
either did not receive antiviral treatment or received it later
than 3 days after the onset of symptoms in comparison to the
patients who received it within the ﬁrst 3 days of symptoms
(median 7 days, IQR: 4–11 versus 5, IQR: 3–7.5; p 0.04). The
lag time from onset of symptoms to starting antiviral treatment
was positively correlated with the length of hospital stay
(Spearman q = +0.32; p 0.01). Twenty-seven of 55 patients
(49%) with at least one comorbidity did not receive antiviral
treatment. Length of stay was not different between patients
with and without comorbidity (median 6.5, IQR: 4–10 versus 6,
IQR: 4–11, respectively; p 0.6).
Forty-one of 129 (32%) patients with respiratory symptoms
had chest X-ray opacities. To have chest X-ray opacities in at
least two quadrants was associated with a longer hospital stay
in comparison to those without inﬁltrate or with opacities in
only one quadrant (median 10 days, IQR: 6–13 versus 5, IQR
4–10, respectively; p 0.01).
In 38 of 129 (29%) patients with respiratory symptoms oral
or intravenous corticosteroids were initiated. There were no
differences in length of stay between patients who received
this therapy and patients who did not receive it (median 6,
IQR: 4–11 versus 6, IQR: 4–10; p 0.48).
Severe cases
None of the patients died in this series. Twenty patients
required admission to the paediatric intensive care units
(PICUs), all due to respiratory failure. Eleven of the 20 patients
(55%) were <2 years old; ten (91%) were previously healthy
infants and one had a congenital heart disease. Four of the nine
(44%) patients who were >2 years old had some comorbidity
(two had a neurological impairment, one had asthma, one was
an immunocompromised child). However, to be <2 year old
and/or to have at least one pre-existing condition was not
associated with a higher frequency of requiring admission to
PICU in comparison to healthy children >2 years old: ﬁve of 41
(12%) previously healthy children aged >2 years required PICU
admission and a similar rate, 15 of 102 (15%), of those aged
<2 years and/or who had at least one pre-existing condition
required PICU admission (p 0.7).
Seven of the 22 (32%) children with chest X-ray opacities in
more than one quadrant required admission to PICU, whereas
13 of 121 (11%) patients without chest X-ray opacities or with
opacities in only one quadrant were admitted to the PICUs
(p <0.01).
Eighteen of the 86 (21%) patients who did not receive
antiviral therapy or who received it more than 3 days after the
onset of symptoms were admitted to the PICU whereas only
two of the 25 (8%) patients who received antiviral agents
within the ﬁrst 3 days of symptoms were admitted to the
PICU (both of them were previously healthy patients aged
<2 years). This difference was not statistically signiﬁcant
(p 0.23).
TABLE 1. Main clinical and epidemiological variables among
the 143 children who required hospitalization.
Reasons for admission, n (%)
Respiratory failure or respiratory distress 123 (86)
Fever with a high-risk condition 6 (4)
Vomiting requiring intravenous hydration 6 (4)
Seizures and other neurological symptoms 4 (3)
Others 4 (3)
Age (median, IQR)a 2.0 years (1.0–6.0)
Patients without comorbidity 1.8 years (1.0–3.0)
Patients with comorbidity/ies 5.3 years (1.3–10.7)
Comorbidity, n (%)
None 88 (62)
Pulmonary conditions 26 (47)
Neurological disease 23 (42)
Cardiovascular disease 5 (4)
Renal chronic disease 4 (3)
Diabetes mellitus 1 (1)
Primary or secondary immunodeﬁciency 7 (5)
Patients with two or more pre-existing conditions 10 (7)
Main clinical symptoms, n (%)
Fever 133 (93)
Respiratory symptoms 129 (90)
Gastrointestinal symptoms 57 (40)
Myalgia 38 (27)
Headache 25 (17)
Other neurological symptoms 25 (17)
Length of hospital stay (median, IQR)b 6 days (4–10)
Patients without comorbidity 6 days (IQR: 4–11)
Patients with comorbidity/ies 6.5 days (IQR: 4–10)
Use of antiviral agents during hospitalization, n (%)c
Within the ﬁrst 72 h of clinical symptoms 25 (23)
More than 72 h after the onset of symptoms 44 (40)
Chest X-ray, n (%):
Absent or without opacities 102 (71)
Opacities in one quadrant 19 (13)
Opacities in more than one quadrant 22 (15)
Patients who required PICU admission, n (%) 20 (14)
aThe median age was lower in patients without comorbidity (p <0.01).
bLength of stay was not different between patients with and without comorbidity
(p 0.6).
cOver 111 patients. These data were not recorded in 32 patients.
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Risk factors for hospitalization
For the case–control analysis we included 135 admitted
patients and 137 outpatients (Table 2). Having a neurological
disease conferred the highest risk of requiring admission
(adjusted OR 17.18; 95% CI 3.44–85.90) in the multivariate
analysis. Other variables that were related to admission were
having a chronic pulmonary disease, having neurological
symptoms due to the inﬂuenza infection, having a longer
duration of symptoms, receiving antibiotics before consulting,
and being a child of parents with a lower educational level.
Only two of the patients who required hospitalization had
been receiving antiviral agents before admission (both with an
underlying condition). None of the outpatients received
antiviral agents.
Discussion
This is one of the ﬁrst paediatric postpandemic series in
international literature that allows us to describe inﬂuenza
during the 2010–2011 season in a representative sample of
children admitted to 17 Spanish hospitals and to study speciﬁc
risk factors for a more severe disease requiring hospitalization
using a design of a matched case–control study.
Most of the admitted children with inﬂuenza infection did
not have any comorbidity. This is similar to other prepandemic
paediatric reports [10,11]. The age distribution of hospitaliza-
tions was in accord with the pattern of children aged <2 years
without comorbidities and older children with some previ-
ously known disease, as observed by others during the
pandemics [12,13]. In another series that included patients of
all ages [4], the hospitalized patients in the immediate post-
pandemic period were signiﬁcantly older than those admitted
during the 2009 pandemic season. However, focusing on
paediatrics, we observed that the median age of the infected
children was lower in comparison with the median age of
those who were infected during the pandemic season [14].
This observation was also made by Poulakou et al. [9]. Older
children might have been less susceptible because of a
relatively high attack rate during the previous pandemic
inﬂuenza season [15]. Of note, although inﬂuenza vaccine
coverage was very low, it was almost non-existent among
patients <2 years old in our series and most of the patients
with comorbidities were not well immunized. In Spain, the
inﬂuenza vaccine is administered free of charge to patients
with some high-risk conditions. Some studies have reported
that lower patient volume and strategies to extend the opening
hours of vaccine ofﬁces/clinics to evenings and weekends have
TABLE 2. Epidemiological and clinical variables as risk factors for hospitalization.
Hospitalized
(n = 135)
Outpatients
(n = 137)
Univariate analysis Multivariate analysisa
Crude OR
(95% CI) p value
Adjusted OR
(95% CI) p value
Age (median), n (%) 2.0 years (IQR: 1.0–6.0) 2.6 years (IQR: 1.2–6.3) 1.02 (0.91–1.14) 0.69
<2 years 59 (44) 57 (42) 1
2–5 years 36 (27) 39 (28) 0.81 (0.36–1.81) 0.61
5–12 years 30 (22) 34 (25) 0.91 (0.34–2.43) 0.86
 13 years 10 (7) 7 (5) 2.00 (0.38–10.36) 0.41
Sex (male), n (%) 68 (50) 65 (47) 0.88 (0.54–1.44) 0.62
Comorbidities, n (%)
Patients with one or more pre-existing
conditions
52 (38) 14 (10) 7.55 (3.22–17.72) <0.001
Pulmonary disease 24 (18) 12 (9) 2.57 (1.13–5.84) 0.02 3.31 (1.01–10.88) 0.04
Neurological disease 22 (16) 2 (1) 11.86 (2.78–50.58) 0.001 17.18 (3.44–85.90) 0.001
Cardiovascular disease 5 (4) 0 (0) 65.29 (0.05–86658.5) 0.25
Renal chronic disease 4 (3) 0 (0) 65.29 (0.02–202501.6) 0.31
Diabetes mellitus 1 (1) 0 (0) 65.29 (0–6.3e8) 0.61
Primary or secondary immunodeﬁciency 7 (5) 0 (0) 65.29 (0.15–28459.84) 0.18
Patients with two or more pre-existing
conditions
10 (7) 0 (0) 65.29 (0.40–10546.6) 0.11
Full inﬂuenza vaccination coverage 5 (4) 2 (1) 4.00 (0.45–35.79) 0.21
Full pneumococcal vaccine, PCV7,
immunization
41 (31) 51 (39) 0.68 (0.36–1.28) 0.23
Non-Caucasian ethnicity 37 (27) 16 (12) 2.66 (1.40–5.04) 0.003
Parents with primary or lower education 44/127 17/136 4.19 (2.02–8.68) <0.001 6.21 (2.47–15.65) <0.001
Clinical symptoms, n (%)
Fever 125 (93) 119 (87) 1.89 (0.84–4.24) 0.12
Respiratory symptoms 121 (89) 111 (81) 2.15 (1.01–4.58) 0.04
Digestive symptoms 56 (41) 32 (23) 2.57 (1.44–4.59) 0.001
Neurological symptoms 25 (18) 3 (2) 8.33 (2.52–27.60) 0.001 4.75 (1.03–21.83) 0.04
Days of clinical symptoms,
median (IQR)
3 (IQR: 1–5) 2 (IQR: 1–3) 1.23 (1.10–1.38) <0.001 1.20 (1.01–1.43) 0.04
Antibiotics before consulting,
n (%)
48 (36) 24 (18) 3.29 (1.67–6.50) 0.001 2.70 (1.14–6.38) 0.02
aArea under the curve = 0.73; Hosmer–Lemeshow: p 0.48.
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been associated with higher rates of vaccine coverage [16].
However, to promote information about the safety and
immunogenicity of inﬂuenza vaccination among paediatricians
and the target population is also important [17]. With regard
to universal child vaccination, it may be an appropriate public
health priority because vaccination is both cost saving and cost
effective; children have high rates of healthcare utilization due
to inﬂuenza and are the main transmitters of the virus [18].
Almost all the patients had respiratory symptoms and
respiratory distress and hypoxaemia were the main reasons
for hospitalization in our series. Severity of illness was
comparable among prepandemic, pandemic and postpandemic
seasons as stated by Rahamat-Langendoen et al., but more
radiographic pneumonia was diagnosed in patients with
inﬂuenza A(H1N1)pdm09 [4,6]. It is well know that having
viral pneumonia was a risk factor for admission due to
inﬂuenza disease in children [5,19]. We observed that having
chest X-ray opacities in two or more quadrants was associated
with a longer hospital stay and a higher risk of PICU admission.
Less than a half of the hospitalized children received antiviral
agents and there were also children with high-risk conditions
who did not received oseltamivir. During the ﬁrst postpan-
demic season the use of antiviral agents has probably been too
low compared with their use during the pandemic outbreak
[20]. In our opinion, this could increase the risk of severe
disease, as stated in other studies [2,21], and it caused a longer
hospital stay in our series, as observed during the pandemic
season [22]. There are still controversies in the use of
antivirals in children; ﬁrst, because of the ill-deﬁned conclu-
sions of several trials and meta-analyses published before the
pandemics; although the evidence supports a direct mechanism
of action for oseltamivir on symptoms [23]. On the other
hand, there may be a fear that widespread use of antiviral
agents facilitates the expansion of resistant viruses [24]. We
are still unable to draw conclusions about the effect of antiviral
treatment on complications or transmission as stated by the
last Cochrane review about neuraminidase inhibitors for
preventing and treating inﬂuenza in children [23], but the
results of several observational studies published elsewhere
support the use of antiviral agents in children with risk of
severe disease [25]. Children who require hospitalization and
those outpatients with a high-risk condition should be
considered for antiviral treatment.
Regarding other treatments, no differences in length of
hospital stay were observed between children who received
systemic corticosteroids and patients without corticosteroids
in this study. There are no speciﬁc guidelines for using this
treatment in children with inﬂuenza infection, even in those
with severe inﬂuenza disease. Studies in adult settings have
shown no beneﬁt of using corticosteroids or other immuno-
modulatory treatments [26,27], despite observing an exagger-
ated inﬂammatory response in several cases of severe inﬂuenza
disease [28]. There is not much information regarding the role
of immunopathology in severe inﬂuenza disease in children
[29]. The adult immune response cannot be extrapolated to
children, and direct viral damage could be important enough to
cause severe manifestations in children [30]. In our opinion,
there could be high diversity in corticosteroid use in our
series, so this is a variable that is difﬁcult to analyse. Similarly,
we did not ﬁnd much speciﬁc information on antibiotic
therapies, but it is remarkable that patients with antibiotic
treatment were more likely to be admitted than patients
without antibiotics. It is probable that some patients had been
receiving antibiotics empirically because they had symptoms of
a more severe respiratory disease before being admitted.
Finally, according to the results we obtained for the
pandemic season [14], children with a previously known
disease (especially neurological and pulmonary), and children
of parents with lower educational levels were more frequently
admitted to the case–control study analysis. Speciﬁc strategies
to promote the prevention of severe inﬂuenza disease in these
children should be considered.
The main limitations of this study are that it is an
observational report and treatments (antiviral agents, antibi-
otics, corticosteroids) were given according to each partici-
pating hospital’s guidelines. Different criteria for hospital and
PICU admission may also be one of the biases of the study.
To summarize, inﬂuenza disease in the paediatric population
requiring hospitalization during the ﬁrst postpandemic season
in Spain affected mainly children with neurological or pulmo-
nary comorbidities and children of parents with a low
educational level, as reported elsewhere during the pandemics
and other pre-2009 pandemic outbreaks. Most of the inﬂuenza
infections caused respiratory symptoms, although neurological
manifestations were also observed and those patients were
more frequently admitted. Early initiation of oseltamivir was
associated with a shorter length of hospital stay.
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